05/12/22 10:51 AMNasdaq : AUTL conferencesclinical trialAutolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma - AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia - obe-cel: poster presentation in r/r primary CNS lymphoma - obe-cel: poster presentation in r/rRHEA-AIneutral
05/05/22 7:00 AMNasdaq : AUTL earningsAutolus Therapeutics Reports First Quarter 2022 Financial Results and Operational ProgressAutolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational andRHEA-AIneutral
05/02/22 4:31 PMNasdaq : AUTL conferencesAutolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies,RHEA-AIneutral
04/25/22 7:01 AMNasdaq : AUTL FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALLAutolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine AdvancedRHEA-AIneutral
04/25/22 7:00 AMNasdaq : AUTL conferencesearningsAutolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2022 financial results and operational highlights beforeRHEA-AIneutral
03/31/22 7:00 AMNasdaq : AUTL Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic LeukemiaAutolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the European Medicines Agency (EMA) has granted obe-cel, Autolus’ leading CAR T clinicalRHEA-AIvery positive
03/29/22 7:00 AMNasdaq : AUTL conferencesAutolus Therapeutics to Participate in Conferences During April 2022RHEA-AIneutral
03/10/22 7:00 AMNasdaq : AUTL earningsAutolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational ProgressAutolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational andRHEA-AIneutral
03/03/22 7:00 AMNasdaq : AUTL Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology- Publication describing a novel technology that provides for very low levels of expression of one programming module relative to another programming module 1 - Method for expressing stable low levels of a toxic gene - technology deployed in Autolus’ approach for the treatment of solid tumors -RHEA-AIneutral
02/21/22 7:00 AMNasdaq : AUTL conferencesearningsAutolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2021 financial results and operationalRHEA-AIneutral